Fewer than one in five eligible individuals in the United States are up-to-date with recommended lung cancer screening, according to a study led by American Cancer Society researchers.
Daiichi Sankyo and Merck have expanded their existing global co-development and co-commercialization agreement for three investigational DXd antibody-drug conjugates to include Merck’s MK-6070, an investigational delta-like ligand 3 targeting T-cell engager.
